Abstract
Positron emission tomography (PET) is an established medical diagnostic imaging method. Continuous improvements are aimed at refining image reconstruction, reducing the amount of radioactive tracer and combining with targeted therapy. Time-of-flight (TOF)-PET provides the localization of the tracer through improved time resolution, nuclear physics may contribute to this goal via selection of radioactive nuclei emitting additional γ-rays. This additional radiation, when properly detected, localizes the decay of the tracer at the line of response (LoR) determined by two detected 511 keV quanta. Selected candidates are presented. Some are particularly interesting, as they are strong candidates for theranostic applications.
Acknowledgments
I am grateful to Dr. Mateusz Sitarz and the late professor Jerzy Jastrzȩbski for pointing to me their vision of medical applications of nuclear physics. The help of Joanna Matulewicz in making graphics is acknowledged.
Research funding: None declared.
Author contributions: Author has accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Author states no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. NuPECC long range plans; 2017. Available from: http://www.nupecc.org/lrp2016/Documents/lrp2017.pdf.Search in Google Scholar
2. Levin, CS, Hoffman, EJ. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol 1999;44:781. https://doi.org/10.1088/0031-9155/44/3/019.Search in Google Scholar
3. Sharma, A, McConathy, J. Overview of PET tracers for brain tumor imaging. Pet Clin 2013;8:129–46. https://doi.org/10.1016/j.cpet.2013.02.001.Search in Google Scholar
4. Huang, YY. An overview of PET radiopharmaceuticals in clinical use: regulatory, quality and pharmacopeia monographs of the United States and Europe. In: Nuclear medicine physics. IntechOpen; 2018.10.5772/intechopen.79227Search in Google Scholar
5. NIST Standard Reference Database 8. https://doi.org/10.18434/T48G6X.Search in Google Scholar
6. Lois, C, Jakoby, BW, Long, MJ, Hubner, KF, Barker, DW, Casey, ME, et al.. An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging. J Nucl Med 2010;51:237–45. https://doi.org/10.2967/jnumed.109.068098.Search in Google Scholar
7. Lecoq, P, Morel, C, Prior, JO, Visvikis, D, Gundacker, S, Auffray, E, et al.. Roadmap toward the 10 ps time-of-flight PET challenge. Phys Med Biol 2020;65:21RM01. https://doi.org/10.1088/1361-6560/ab9500.Search in Google Scholar
8. Sitarz, M, Cussonneau, JP, Matulewicz, T, Haddad, F. Radionuclide candidates for β+γ coincidence PET: an overview. Appl Radiat Isot 2020;155:108898. https://doi.org/10.1016/j.apradiso.2019.108898.Search in Google Scholar
9. Sæterstøl, J. Characterization of scintillation crystals for positron emission Tomography [PhD thesis]. University of Bergen Bergen: Bergen, Norway; 2010.Search in Google Scholar
10. Sitarz, M. Radionuclide yield calculator. Available from: https://www.arronax-nantes.fr/en/outil-telechargement/tool-radionuclide-yield-calculator/.Search in Google Scholar
11. Goethals, PE, Zimmermann, RG. Cyclotrons used in nuclear medicine 2020th ed; 2020. Available from: http://medraysintell.com.10.1051/978-2-7598-2149-5Search in Google Scholar
12. Synowiecki, MA, Perk, LR, Nijsen, JFW. Production of novel diagnostic radionuclides in small medical cyclotrons. EJNMMI Radiopharm Chem 2018;3:3. https://doi.org/10.1186/s41181-018-0038-z.Search in Google Scholar
13. Leszek, K. Present and future of theranostics, 2021;17:213–20.10.1515/bams-2021-0169Search in Google Scholar
14. Alberto, R, Schibli, R, Waibel, R, Abram, U, Schubiger, AP. Basic aqueous chemistry of [M(OH2)3(CO)3]+(M=Re,Tc) directed towards radiopharmaceutical application. Coord Chem Rev 1999;190–192:901. https://doi.org/10.1016/S0010-8545(99)00128-9.Search in Google Scholar
15. Kazakov, AG, Ekatova, TY, Babenya, JS. Photonuclear production of medical radiometals: a review of experimental studies. J Radioanal Nucl Chem 2021;328:493–505. https://doi.org/10.1007/s10967-021-07683-2.Search in Google Scholar
16. Loveless, CS, Radford, LL, Ferran, SJ, Queern, SL, Shepherd, MR, Lapi, SE. Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide Sc-47. EJNMMI Res 2019;9:42. https://doi.org/10.1186/s13550-019-0515-8.Search in Google Scholar
17. Gizawy, MA, Mohamed, NMA, Aydia, MI, Soliman, MA, Shamsel-Din, HA. Feasibility study on production of Sc-47 from neutron irradiated Ca target for cancer theranostics applications. Radiochim Acta 2020;108:207–15. https://doi.org/10.1515/ract-2018-3070.Search in Google Scholar
18. Carzaniga, TS, Auger, M, Braccini, S, Bunka, M, Ereditato, A, Nesteruk, KP, et al.. Measurement of Sc-43 and Sc-44 production cross-section with an 18 MeV medical PET cyclotron. Appl Radiat Isot 2017;129:96–102. https://doi.org/10.1016/j.apradiso.2017.08.013.Search in Google Scholar
19. Sitarz, M, Szkliniarz, K, Jastrzebski, J, Choinski, J, Guertin, A, Haddad, F, et al.. Production of Sc medical radioisotopes with proton and deuteron beams. Appl Radiat Isot 2018;142:104–12. https://doi.org/10.1016/j.apradiso.2018.09.025.Search in Google Scholar
20. Carzaniga, TS, Braccini, S. Cross-section measurement of Sc-44m,Sc-47, Sc-48 and Ca-47 for an optimized Sc-47 production with an 18 MeV medical PET cyclotron. Appl Radiat Isot 2019;143:18–23. https://doi.org/10.1016/j.apradiso.2018.10.015.Search in Google Scholar
21. Szelecsenyi, F, Kovacs, Z, Nagatsu, K, Zhang, MR, Suzuki, K. Production cross sections of radioisotopes from He-3-particle induced nuclear reactions on natural titanium. Appl Radiat Isot 2017;119:94–100. https://doi.org/10.1016/j.apradiso.2016.10.016.Search in Google Scholar
22. Peplowski, PN. Cross sections for the production of radionuclides via Cu-nat(p,X) spallation reactions for proton energies from 250 MeV to 2 GeV. Nucl Phys 2020;A1006:122067. https://doi.org/10.1016/j.nuclphysa.2020.122067.Search in Google Scholar
23. Muller, C, Domnanich, KA, Umbricht, CA, van der Meulen, NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol 2018;91:20180074. https://doi.org/10.1259/bjr.20180074.Search in Google Scholar
24. Huclier-Markai, S, Alliot, C, Kerdjoudj, R, Mougin-Degraef, M, Chouin, N, Haddad, F. Promising scandium radionuclides for nuclear medicine: a review on the production and chemistry up to in vivo proofs of concept. Cancer Biother Rad 2018;33:316–29. https://doi.org/10.1089/cbr.2018.2485.Search in Google Scholar
25. Hovhannisyan, GH, Bakhshiyan, TM, Dallakyan, RK. Photonuclear production of the medical isotope 67Cu. Nucl Instrum Methods Phys Res 2011;B498:48–51. https://doi.org/10.1016/j.nimb.2021.04.016.Search in Google Scholar
26. Nigron, E, Guertin, A, Haddad, F, Sounalet, T. Is 70Zn(d, x)67Cu the best way to produce 67Cu for medical applications? Front Med 2021;8:1059. https://doi.org/10.3389/fmed.2021.674617.Search in Google Scholar
27. McInnes, LE, Cullinane, C, Roselt, PD, Jackson, S, Blyth, BJ, van Dam, EM, et al.. Therapeutic efficacy of a bivalent inhibitor of prostate-specific membrane antigen labeled with 67Cu. J Nucl Med 2021;62:829–32. https://doi.org/10.2967/jnumed.120.251579.Search in Google Scholar
28. Vandenberghe, S, Moskal, P, Karp, JS. State of the art in total body PET. EJNMMI Phys 2020;7:35. https://doi.org/10.1186/s40658-020-00290-2.Search in Google Scholar
© 2021 Walter de Gruyter GmbH, Berlin/Boston
